Indications
Ziihera as monotherapy is indicated for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy (for biomarker-based patient selection, see section 4.2).
Composition
- Active substance
- zanidatamab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ziihera
- Active substance
- zanidatamab
- ATC code
- L01FD07
- Therapeutic area
- Biliary Tract Neoplasms
- Marketing authorisation holder
- Jazz Pharmaceuticals Ireland Limited